Introduction
Using standard chemotherapy regimens, most patients with newly diagnosed acute leukemia relapse and ultimately die from their disease. 1 In an attempt to improve upon these results many investigators have developed more intensive chemotherapy regimens, including high-dose ara-C-based induction chemotherapy 2 and transplantation as consolidation therapy. 3, 4 Increased intensity of treatment may result in more patients presenting with secondary malignancies as a result of their treatment, partially because more patients are surviving their original disease and partially because the treatment they received was carcinogenic.
Traditionally, secondary leukemias have been divided into two groups, those following treatment with alkylating agents, and those following topoisomerase II inhibitors. Leukemias occurring after exposure to alkylating agents typically have a long latency period (5 or more years), are often preceded by an MDS phase, and frequently show deletions or loss of chromosomes 5 and 7 on cytogenetic analysis. 5 In contrast, leukemias occurring following exposure to topoisomerase II inhibitors classically have a short latency period (2 years), have no prior MDS phase, and demonstrate cytogenetic abnormalities involving chromosome 11q23. 6, 7 Newer studies suggest that the spectrum of cytogenetic abnormalities following chemotherapy is in fact broader and includes deletions of chromo- somes other than 5 and 7, as well as a variety of balanced translocations. 8, 9 For example, several authors have reported secondary AML with t(8;21), t(15;17), or t(9;22) following topoisomerase II inhibitors. [10] [11] [12] Although secondary cytogenetic abnormalities following chemotherapy are frequently associated with secondary AML and/or MDS, in other cases the significance of the changes is less certain. Lambertenghi Deliliers et al 13 analyzed cytogenetic and myelodysplastic alterations in 83 patients who underwent autologous transplantation for a variety of hematologic malignancies. Twelve patients developed non-clonal cytogenetic abnormalities and 10 patients developed clonal abnormalities, five of whom developed MDS/AML a median of 14 months after autografting. Others have also shown that patients may develop non-clonal or clonal cytogenetic abnormalities that remain stable or even undergo spontaneous resolution. Imrie et al 9 reported new cytogenetic abnormalities in seven of 62 patients with AML who underwent autologous transplantation using a melphalan/etoposide/TBI conditioning regimen. After a median follow-up of 30 months, only one patient developed features suggestive of MDS and no patient developed AML. Similar results were reported by Raynaud et al 8 in 39 patients with AML treated with intensive CCNUbased chemotherapy. Seven of these patients developed cytogenetic abnormalities in complete remission that were not associated with hematologic disease. Spontaneous resolution of treatment-related MDS has also been reported in childhood ALL. 14 At New York Medical College we developed a topoisomerase II-intensive acute leukemia induction regimen consisting of a single high dose of mitoxantrone (80 mg/m 2 ) combined with a once daily dose of ara-C (3 g/m 2 ) given for 5 days. This regimen is based on in vitro data showing that mitoxantrone has a very steep dose-response curve in tumor cell lines. 15 In a phase II study of this regimen in AML, the complete response rate was 80% and the observed disease-free survival at 3 years was 25%. 16 In ALL, eight of eight newly diagnosed patients and eight of 10 relapsed patients achieved a complete remission using this regimen. 17 As a result, this regimen and a similar one incorporating a single high dose of idarubicin (40 mg/m 2 ) in combination with the same schedule of ara-C are being used in the treatment of ALL. 18 In an attempt to define the long-term hematologic toxicity of this regimen we reviewed the incidence and outcome of secondary hematologic and cytogenetic abnormalities in all of our newly diagnosed leukemia patients treated with this high-dose mitoxantrone regimen over an 8 year period.
Materials and methods
We reviewed the cytogenetic data of patients who received high-dose mitoxantrone induction therapy on five different studies: 21 A phase II study of high-dose ara-C and high-dose mitoxantrone induction in patients with newly diagnosed ALL (ALL-2 protocol). Patients received intensive consolidation therapy with vincristine, prednisone, L-asparaginase, methotrexate, followed by etoposide and infusional ara-C. Patients then received 2 years of L-20 maintenance therapy.
Study 4 (15 patients)

Study 5 (six patients)
A randomized phase III trial comparing high-dose mitoxantrone and ara-C (ALL-2) vs L-20 induction therapy in newly diagnosed ALL (the ALL-4 protocol). Only patients randomized to the ALL-2 arm are included in this report.
Patients in remission underwent bone marrow aspiration with cytogenetic testing prior to treatment and at the time of remission. Subsequently, patients underwent routine bone marrow aspiration and biopsy to monitor for recurrent disease. Patients with cytogenetic abnormalities at the time of diagnosis had cytogenetic testing at the time of each subsequent bone marrow aspiration. Patients with normal cytogenetics at diagnosis were not required to and generally did not have repeat cytogenetic testing in the absence of overt hematologic disease.
Cytogenetic studies
Karyotypic analysis was performed on short-term (24 h) cultures of bone marrow samples using standard cytogenetic procedures. 22 Air-dried slides were G-banded by the GTG method. 23 The karyotypes were expressed according to ISCN (1995) . 24 The cytogenetic risk groups were defined as follows: AML: good risk, t(8;21), t (15;17) 
Histopathology review
Bone marrow aspiration and biopsy samples of the patients with cytogenetic abnormalities were examined by the same pathologist (JW) prior to knowledge of the cytogenetic abnormalities. Subsequently, the slides were again reviewed with the knowledge of the cytogenetic abnormality to determine if there was any evidence of myelodysplasia.
Results
Between 21 October 1991 and 21
October 1999 newly diagnosed leukemia patients were treated with high-dose mitoxantrone-based chemotherapy. One hundred and forty-two patients had AML, and 21 had ALL. The median age was 54 years (range 19-88) and 54% were male. Nineteen patients had good risk cytogenetics, 73 had intermediate risk cytogenetics, and 57 had poor risk cytogenetics. Fourteen patients had insufficient metaphases at diagnosis. Overall, 108 (66.3%) achieved a complete remission. Fifty-eight patients (35.6%) subsequently relapsed and eight (4.9%) died in remission due to complications of post-remission therapy (including allogeneic transplantation). Forty-two patients (25.8%) remain in remission after a median follow-up of 23.2 months. The median survival for all patients is 10.0 months. The median survival for responding patients is 19.0 months.
We discovered new cytogenetic changes in nine patients (5.5%) after treatment with high-dose mitoxantrone. Since patients without cytogenetic abnormalities at initial diagnosis were not required to have follow-up cytogenetic studies, this figure could be an underestimate of the true incidence. It is unlikely that these abnormalities were present at diagnosis because in all cases sufficient metaphases were examined to exclude that possibility. The median time to the development of the abnormalities was 30 months (range 12-38 months) ( Figure 1 ). Patients who developed secondary cytogenetic abnormalities were younger, and were more likely to have good risk cytogenetics, longer remission duration and longer survival compared to patients who did not develop secondary cytogenetic abnormalities (Table 1) . Table 2 summarizes the clinical course of these patients and Table 3 summarizes the cytogenetic data.
Four patients developed cytogenetic abnormalities that were associated with the development of MDS that subsequently progressed to AML. Interestingly, two of these patients had clinical evidence of neurofibromatosis (NF-1) and have previously been reported. 25 Patient No. 1 was a 34-yearold man with NF-1 who achieved CR on study 1 for AML with 47, XY,+8 [13/20] 47, idem, der (7)t(7;11)(q32;q13), [7/20] . One year after initial diagnosis he developed slowly progressive thrombocytopenia. Bone marrow aspirations for the next 2
Figure 1
Kaplan-Meier curve demonstrating time to development of secondary cytogenetic abnormalities. Patients without these abnormalities were censored at the time of their death or at last follow-up for surviving patients. 
Discussion
Many reports have shown that patients develop secondary AML with abnormalities of chromosome 11q23 following treatment with topoisomerase II inhibitors. 6, 7 Traditionally, these leukemias occur after a short latency period, are not associated with a prior MDS phase, and have monocytic or myelomoncytic morphology. 6, 7 Our data, in association with other reports, suggest that the spectrum of secondary leukemias occurring following topoisomerase II inhibitors is much broader. Our patients developed a variety of cytogenetic abnormalities and frequently demonstrated MDS prior to the development of overt AML. These changes were more common in patients with good risk cytogenetics (especially t(8;21)) presumably due to the patients' prolonged survival following their initial diagnosis in these cases. Instead of involving chromosome 11q23, the abnormalities most often involved chromosomes 7q, 20q, 1q and 13q. Although the changes seen were associated with either relapse or secondary leukemia in most patients, three patients developed new cytogenetic abnormalities that were not clinically significant. The latter cases provide further evidence that some new cytogenetic abnormalities are not necessarily a harbinger of hematologic disease. Rather, it is possible that some cytogenetic abnormalities are either secondary events, or are by themselves insufficient to cause leukemogenesis.
Molecular studies are currently attempting to identify the genes that are responsible for leukemic transformation in patients with MDS and/or t-AML. In a series of 81 patients with de novo MDS or AML and abnormalities of chromosome 7, Le Beau et al 26 determined that there were two distinct deleted segments of 7q. In the majority of the patients (80%) the commonly deleted segment could be localized to chromosome band 7q22. In the remaining patients (20%) the commonly deleted segment was localized to chromosome bands 7q32-33. Further molecular studies by other authors supports the presence of multiple critical loci on chromosome 7 leading to the development of MDS and AML. 27, 28 In the current study six patients developed new abnormalities involving chromosome arm 7q. This abnormality resolved spontaneously in two patients but progressed to AML in four other patients. Of the patients who had spontaneous resolution, one had del(7)(q21.2q32), and the other showed del(7)(q32). The abnormalities in the four patients who progressed were t(7;20)(q22;q11.2), del (7)(q11.2q22), del (7)(q22q36), and −7, respectively. It is unclear if the difference between progression vs resolution was related to the specific genes deleted or to other contributing genetic factors. The latter is supported by the fact that two of the patients with progression had NF-1 with loss of a known tumor suppressor gene. Cooperation between genetic predisposing states such as NF-1 and chemotherapy agents in the development of myeloid malignancies was demonstrated by Mahgoub et al 29 in an Nf1+/− mouse model. Fourteen percent of untreated Nf1+/− mice developed a myeloproliferative disorder (MPD), whereas 25% of etoposide-treated mice and 38% of cytoxan-treated mice developed MPD. In each case the incidence of MPD was higher in Nf1+/− mice than in Nf1+/+ control mice treated with the same agents. This study provided direct experimental evidence that exposure to some commonly used chemotherapy agents can cooperate with a constitutional genetic predisposition toward malignancy.
In the current study, four patients developed abnormalities of 20q11.2. In one patient, the abnormality resolved spontaneously, in another it persists in the absence of hematologic disease. The two patients who had this abnormality at the time of relapse had additional cytogenetic abnormalities including a translocation involving 7q22 [t(7;20)(q22;q11.2)] in one patient, and abnormalities of chromosomes13q and 7(q22q36) in the other. Kurtin et al 30 reported 107 cases of hematologic disorders associated with deletions of chromosome 20q. The range of diseases included MDS (60 patients), myeloproliferative disorders (37 patients), AML (five patients), pure red cell dysplasia (two patients), AILD (one patient), and autoimmune diseases (two patients). In this heterogeneous group of patients the bone marrow abnormalities consistently involved erythroid precursors and megakaryocytes. Although early reports suggested that MDS with 20q− was associated with a poor prognosis, 31 newer reports indicate that the outcome of these patients is good. Wattel et al 32 reported eight cases of de novo MDS with del 20q from a larger series of 392 patients with MDS. The median survival was 42 months. Only patients with isolated del 5q had a longer survival. In the reports of Imrie et al 9 and Raynaud et al 8 three patients with 20q− had no evidence of hematologic disease, and one patient developed MDS. The latter patients in combination with the current report suggest that abnormalities of 20q− by itself may be insufficient to cause leukemogenesis.
In the current report, two patients developed abnormalities of chromosome arm 1q. In one patient the abnormality is present in the absence of hematologic disease. A second patient developed additional cytogenetic changes [t(7;13)(p11.2;q12)] and subsequently progressed to AML. Clonal rearrangements of chromosome 1q have been reported in patients with de novo MDS. 33 In one report, partial or total trisomy of chromosome arm 1q was associated with young age at onset (median 36.5 years), nonaggressive clinical course, and a hypocellular bone marrow. 34 In the previous reports of Imrie et al 9 and Raynaud et al 8 two patients developed dup (1)(q12q31) after chemotherapy. Neither of these patients developed overt hematologic disease. These data suggest that abnormalities of chromosome arm 1q following chemotherapy are associated with a good prognosis.
One patient in the current report developed a late onset Philadelphia chromosome. The Philadelphia chromosome occurs in nearly all cases of chronic myelogenous leukemia and occurs frequently in older patients with ALL. However, the Philadelphia chromosome has also been reported to occur in cases of MDS and AML. 35, 36 In the latter cases the Philadelphia chromosome can occur at diagnosis, or, rarely as a late event. 37 Pedersen-Bjergaard et al 12 reported the development of Philadelphia chromosome-positive secondary leukemias in 25 patients treated with topoisomerase II inhibitors for other malignancies. These authors also proposed that exposure to topoisomerase II inhibitors could lead to a variety of balanced translocations and inversions arising as non-homologous chromosomal recombinations of topoisomerase II-induced double-strand breaks of DNA. The latter is supported by other studies showing development of secondary APL as well as AML with t(8;21) following exposure to topoisomerase II inhibitors. 10, 11 In conclusion, we report the development of several secondary cytogenetic abnormalities in patients treated with high-dose mitoxantrone-based therapy for acute leukemia. In some cases these changes were associated with relapse or secondary leukemia. In others the changes were not clinically significant. The cytogenetic changes were similar to those reported following alkylating agent-based chemotherapy for hematologic malignancies. As most of the patients in the cur-rent report had no exposure to alkylating agents these data suggest that the cytogenetic changes seen may occur following a variety of toxic exposures. These data also give further support to the theory that some cytogenetic changes are not by themselves intrinsically leukemogenic, but rather work with other constitutional and/or acquired genetic abnormalities to cause disease.
